NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Don’t worry about "Meifud" and its figures. He's not as good at mathematics.This is what he wrote 6 days ago on Yahoo message:

Quote Meifud:
Meifud 6 days ago

“after full enrollment in 2015, even Linda Liau was described as having these concerns with the phase III...
-- "She sounded a cautionary note that the proscribed endpoints for the trial which are median progression free survival or mPFS (primary endpoint) and median overall survival or mOS (secondary endpoint) may not be the right endpoints for the trial...She worries that this could be an issue for the trial."
-- "She also notes that patients who were started on placebo and whose disease progressed were allowed to switch to DCVax-L. This confounds the overall survival analysis as 67% of patients initially received DCVax-L; 19% of control patients received DCVax-L at a later time after their disease progressed; and 14% did not receive DCVax-L. This could confound the analysis of overall survival."


“19% of control patients received DCVax-L at a later time after their disease progressed”???

WE ALL KNOW BETTER!